Will Zimmer Be Medtech ’s Comeback Kid of 2018?

Bryan Hanson knew when he accepted the job of CEO of Zimmer Biomet in December that he had a tall order to fill. The company has struggled with faces quality control and supply chain problems since December 2016, which has created investor frustration that ultimately led to former CEO David Dvorak's resignation last July. In his six weeks on the job, Hanson said he has come to realize that the company's current challenges are even more complex than he had anticipated. But during the company's fourth-quarter earnings call this week, MD+DI identified five reasons that Zimmer Biomet could make a comeback under Hanson's leadership. Learn about smart manufacturing at the MD&M West Conference & Expo, February 6-8, 2018, in Anaheim, CA. Use promo code "MDDI" for 20% off conference registration and free expo access. 1. Trust Matters Hanson said he has spent "as much time as I possibly can with the commercial team so far," including time in the field working one-on-one with sales staff, visiting customers, going to cases, and essentially trying to spend a day walking in their shoes.  "I've had really good exposure early on to the organization," he said, according to Seeking Alpha transcripts of the call. That time on the ground could go a long way toward rebuilding the trust that was lost over the past year. "There's just a lack of trust right now from the sales organization for corporate," Hanson said. "We have given them timelines that we have failed on and they've gon...
Source: MDDI - Category: Medical Devices Authors: Tags: Medical Device Business Orthopedics Source Type: news